This multi-institutional phase II trial (80 patients from 17 Canadian institutions) was performed to assess if a hypofractionated accelerated radiotherapy regimen for cytohistological-proven early stage NSCLC (peripherally located T1 to T3 N0 M0) has a good local control rate. They concluded that delivering 60 Gy in 15 fractions using a simple three-dimensional conformal radiotherapy technique resulted in favorable outcomes in patients with NSCLC who were medically inoperable or refused surgery. The actuarial rate of primary tumor control was 87.4% and overall survival was 68.7% at 2 years. This approach may be a good option for those centers that do not have SBRT/SABR capability.
You are here:
Phase II Study of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy for Stage T1-3 N0 M0 Non–Small Cell Lung Cancer: NCIC CTG BR.25
Source: Journal of the National Cancer Institute
Keywords:
Author(s): Patrick Cheung, Sergio Faria, Shahida Ahmed, Pierre Chabot, Jonathan Greenland, Elizabeth Kurien, Islam Mohamed, James R. Wright, Helmut Hollenhorst, Catherine de Metz, Holly Campbell, Thi Toni Vu, Anand Karvat, Elaine S. Wai, Yee C. Ung, Glenwood Goss, Frances A. Shepherd, Patti O’Brien, Keyue Ding and Chris O’Callaghan
